In a phase I clinical trial in the recruiting stage, a DNA vaccine encoding multiple tumor antigens (including CD105, Yb-1, SOX2, CDH3, MDM2) called STEMVAC, is injected intradermally together with sargramostim (GM-CSF) into patients with stage IV non-small cell lung cancer (NSCLC). The gene discussed is YBX1; the disease is non-small cell lung carcinoma.